Abstract

Genmab A/S will release fiscal second-quarter 2026 results on August 06, 2026 Post Market; this preview outlines consensus forecasts for revenue, margins, and EPS, reviews last quarter’s performance, highlights business mix and growth drivers, and assesses institutional sentiment ahead of the print.

Market Forecast

For the current quarter, consensus points to total revenue of 1.11 billion US dollars, EBIT of 349.91 million US dollars, and adjusted EPS of 0.35, implying year-over-year changes of 24.09% for revenue, 10.42% for EBIT, and -21.09% for EPS. Year-over-year on a like-for-like basis, consensus implies softer EPS despite double-digit top-line expansion, reflecting timing of milestones, operating investment, and product-mix shifts; margin specifics are not explicitly guided by the company for this quarter, though last quarter’s gross margin base was high.

Royalty income remains the largest driver by scale, supported by partner oncology product uptake, while product net sales expand from the company’s own portfolio and collaborations; the revenue mix suggests sustained strength in recurring royalties. The most promising near-term segment is royalties at 742.00 million US dollars last quarter, underpinned by partner commercial momentum and representing the dominant share of quarterly revenue.

Last Quarter Review

In the previous quarter, Genmab A/S reported revenue of 896.00 million US dollars, a gross profit margin of 92.75%, GAAP net profit attributable to shareholders of 53.00 million US dollars, a net profit margin of 5.92%, and adjusted EPS of 0.08, with year-over-year growth of 25.32% for revenue and -72.79% for EPS. Quarter on quarter, net profit attributable to shareholders increased by 70.97%, while the revenue mix remained anchored by recurring royalties.

Main business highlights included royalties at 742.00 million US dollars, product net sales at 116.00 million US dollars, milestone payments at 16.00 million US dollars, collaboration revenue at 14.00 million US dollars, and reimbursement income at 8.00 million US dollars. The revenue base benefited from strong partner sales contributions through royalties, while product net sales and milestones added incremental growth.

Current Quarter Outlook

Main business: Recurring royalties

Royalties are the core earnings engine for Genmab A/S this quarter, with consensus revenue growth of 24.09% for the overall company pointing to continued partner commercial execution in oncology indications. The high gross margin profile from licensing and royalty flows helps maintain an attractive margin base, though EPS guidance suggests operating investments and lower milestone visibility may temper the drop-through to the bottom line. With royalty revenue at 742.00 million US dollars last quarter, the company enters the quarter with a strong recurring base that can absorb volatility from milestones or collaboration timing.

Management’s historical revenue cadence indicates that royalties tend to correlate with prescription demand, broader label penetration, and inventory patterns across partner markets. Given the last quarter’s 92.75% gross margin, the royalty-heavy mix is likely to support another quarter of robust gross profitability even if operating expenses track upward. Any upside surprise would most likely come from better-than-expected partner demand or favorable pricing/mix, while downside risk could arise from channel inventory corrections or regional demand shifts that pressure royalty accruals.

Most promising business: Product net sales expansion

Product net sales at 116.00 million US dollars last quarter are less material than royalties in absolute terms but represent an important lever for multi-year growth as Genmab A/S scales its commercial capabilities. The step-up in internal product contribution, combined with ongoing collaborations, can incrementally improve revenue diversification and strategic control over promotions and lifecycle management. Over time, a higher proportion of product net sales creates potential for operating leverage as fixed commercial infrastructure utilization improves.

In the near term, variability in product uptake, reimbursement timelines, and launch phasing can drive quarter-to-quarter noise relative to the steadier royalty stream. The consensus outlook, with EBIT up 10.42% year over year yet EPS down 21.09%, suggests near-term cost investment accompanying product expansion, which can be constructive for medium-term value creation if early market development primes future revenue compounding. Monitoring unit momentum, new market entries, and formulary wins will be central to gauging whether product net sales can outpace operating expense growth over the next few quarters.

Factors most impacting the stock this quarter

Margin trajectory versus consensus is likely the single most important swing factor for the shares around this print. Last quarter’s 92.75% gross margin provides a high benchmark; investors will scrutinize whether gross margin remains resilient given product-mix shifts and the level of milestone recognition embedded in the quarter. If gross margin holds near the prior quarter’s level and operating expense growth is contained, EPS could track closer to the top end of expectations despite the headline consensus implying a decline year over year.

Second, the cadence and composition of revenue will matter for quality-of-earnings assessments. A heavier mix of recurring royalties is typically viewed as higher quality and more predictable, while milestone-heavy quarters can increase volatility. Clarity on milestone timing for the remainder of the year could decrease uncertainty and support multiple stability. Third, qualitative updates on partnered oncology assets and internal pipeline progress can recalibrate out-year models, especially if partner sell-through data points to sustained volume growth or if regulatory/clinical milestones come into view that might influence future revenue recognition patterns.

Analyst Opinions

Across recent institutional commentary, the prevailing view is bullish, with the majority of analysts highlighting double-digit revenue growth expectations for the quarter, robust royalty fundamentals, and a high gross margin foundation that supports resilient unit economics. Positive viewpoints emphasize that the consensus revenue increase of 24.09% year over year aligns with steady partner demand in key oncology indications, while the EBIT growth expectation of 10.42% indicates ongoing operating discipline despite growth investments. Several well-known firms have underscored the durability of royalty cash flows as the primary anchor for valuation frameworks into the second half of 2026.

Analysts in this majority camp also point out that the gap between revenue growth and EPS decline can be transient, driven by timing effects in milestones and front-loaded operating expense associated with product launches and market expansion. The emphasis is on the potential for incremental upside if royalty accruals outpace current tracking data or if operating expense growth moderates from recent levels. The constructive stance generally prefers quarters characterized by recurring revenues and high gross margins, arguing that such profiles often withstand macro or pricing headwinds better than peers.

From a stock-reaction perspective, bullish analysts argue that margin stability and any sign of normalized milestone cadence could serve as positive catalysts. They expect that if reported gross margin stays close to the last quarter’s level and EBIT prints near the 349.91 million US dollars consensus, investor focus may shift from near-term EPS compression to the sustainability of high-quality revenue growth. Institutions in this group highlight that Genmab A/S’s revenue mix last quarter—dominated by 742.00 million US dollars in royalties—provides a cushion against volatility in smaller revenue lines, supporting confidence in the company’s ability to meet or exceed top-line expectations through the remainder of the year.